Advanced search
Publication Cover
Future Science OA Volume 7, 2021 - Issue 4
Submit an article Journal homepage
848
Views
22
CrossRef citations to date
0
Altmetric
Editorial

Urologic Malignancies: Advances in the Analysis and Interpretation of Clinical Findings

Felice Crocetto1 Department of Neurosciences, Human Reproduction & Odontostomatology, University of Naples Federico II, Naples, 80131, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-4315-7660
ORCID Icon,
Carlo Buonerba2 Department of Oncology & Hematology, Regional Reference Center for Rare Tumors, AOU Federico II of Naples, Naples, 80131, Italy
,
Vincenzo Caputo1 Department of Neurosciences, Human Reproduction & Odontostomatology, University of Naples Federico II, Naples, 80131, Italy
,
Matteo Ferro3 Division of Urology, European Institute of Oncology-IRCCS, Milan, 20122, Italy;4 Centro di Referenza Nazionale per l'Analisi e Studio di Correlazione tra Ambiente, Animale e Uomo, Istituto Zooprofilattico Sperimentale del Mezzogiorno, Portici, Naples, 80055, Italy
,
Francesco Persico5 Department of Urology, Humanitas Clinical & Research Center-IRCCS, Rozzano, Milan, 20089, Italy
,
Francesco Trama6 Andrology & Urogynecological Clinic, Santa Maria Terni Hospital, University of Perugia, Terni, 05100, Italy
,
Ester Iliano6 Andrology & Urogynecological Clinic, Santa Maria Terni Hospital, University of Perugia, Terni, 05100, Italy
,
Sebastiano Rapisarda7 Department of Urology, Ospedale Pederzoli, Peschiera del Garda, Verona, 37019, Italy
,
Maida Bada8 Department of Urology, San Bassiano Hospital, Bassano del Grappa, Vicenza, 36061, Italy
,
Gaetano Facchini9 UOC of Medical Oncology, ASL NA 2 Nord, “S M delle Grazie” Hospital, Pozzuoli, Naples, 80078, Italy
,
Antonio Verde10 Department of Clinical Medicine & Surgery, University Federico II of Naples, Naples, 80131, Italy
,
Sabino De Placido10 Department of Clinical Medicine & Surgery, University Federico II of Naples, Naples, 80131, Italy
&
Biagio Barone1 Department of Neurosciences, Human Reproduction & Odontostomatology, University of Naples Federico II, Naples, 80131, ItalyORCID Iconhttps://orcid.org/0000-0003-4884-132X
ORCID Icon show all
Article: FSO674 | Received 16 Dec 2020, Accepted 21 Dec 2020, Published online: 04 Feb 2021

References

  • SiegelRL , MillerKD , JemalA. Cancer statistics. CA Cancer J. Clin.70, 7–30 (2020).
  • RescignoP , BuonerbaC , BellmuntJet al.New perspectives in the therapy of castration resistant prostate cancer. Curr Drug Targets13, 1676–1686 (2012).
  • PagliucaM , BuonerbaC , FizaziKet al.The evolving systemic treatment landscape for patients with advanced prostate cancer. Drugs79, 381–400 (2019).
  • FerroM , LucarelliG , CrocettoFet al.First-line systemic therapy for metastatic castration-sensitive prostate cancer: an updated systematic review with novel findings. Crit. Rev. Oncol. Hematol.103198. doi: https://doi.org/10.1016/j.critrevonc.2020.103198 (2020) ( Epub ahead of print).
  • BuonerbaC , FerroM , DolcePet al.Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: a systematic review and meta-analysis. Crit. Rev. Oncol. Hematol .151, 102992 (2020).
  • HussainM , MateoJ , FizaziKet al.Survival with olaparib in metastatic castration-resistant prostate cancer. N. Engl. J. Med. doi:10.1056/NEJMoa2022485 (2020) ( Epub ahead of print).
  • PowlesT , ParkSH , VoogEet al.Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N. Engl. J. Med.383, 1218–1230 (2020).
  • MoriK , AbufarajM , MostafaeiHet al.The predictive value of programmed death ligand 1 in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors: a systematic review and meta-analysis. Eur. Urol. doi:10.1016/j.eururo.2020.10.006 (2020) ( Epub ahead of print).
  • CuriglianoG , LamarreJ. Recent eUpdate on cabozantinib and nivolumab for first-line clear cell renal cancer to the ESMO clinical practice guidelines on renal cell carcinoma. Ann.Oncol. doi:10.1016/j.annonc.2020.11.016 (2020) ( Epub ahead of print).
  • ChoueiriTK , PowlesT , BurottoMet al.696O_PR nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase III CheckMate 9ER trial. Ann. Oncol.31, S1159 (2020).
  • BuonerbaC , PondGR , SonpavdeGet al.Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. Future Oncol.9, 889–897 (2013).
  • DiLorenzo G , D'AnielloC , BuonerbaCet al.Peg-filgrastim and cabazitaxel in prostate cancer patients. Anticancer Drugs24, 84–89 (2012).
  • BuonerbaC , DolceP , IaccarinoSet al.Outcomes associated with first-line anti-PD-1/PD-L1 agents vssunitinib in patients with sarcomatoid renal cell carcinoma: a systematic review and meta-analysis. Cancers (Basel).12, doi:10.3390/cancers12020408 (2020) ( Epub ahead of print).
  • LiuH , YeT , YangXet al.Predictive and prognostic role of PD-L1 in urothelial carcinoma patients with anti-PD-1/PD-L1 therapy: a systematic review and meta-analysis. Dis. Markers8375348–8375348 doi:10.1155/2020/8375348. (2020) ( Epub ahead of print).
  • WeinsteinJN , AkbaniR , BroomBMet al.Comprehensive molecular characterization of urothelial bladder carcinoma. Nature507, 315–322 (2014).

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.